| Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy J Montero, KA Sarosiek, JD DeAngelo, O Maertens, J Ryan, D Ercan, ... Cell 160 (5), 977-989, 2015 | 375 | 2015 |
| Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer UA Matulonis, S Berlin, P Ivy, K Tyburski, C Krasner, C Zarwan, ... Journal of clinical oncology 27 (33), 5601, 2009 | 360 | 2009 |
| Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids SJ Hill, B Decker, EA Roberts, NS Horowitz, MG Muto, MJ Worley Jr, ... Cancer discovery 8 (11), 1404-1421, 2018 | 352 | 2018 |
| Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 NS Horowitz, A Miller, B Rungruang, SD Richard, N Rodriguez, ... Obstetrical & Gynecological Survey 70 (6), 390-392, 2015 | 287 | 2015 |
| Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer NS Horowitz, F Dehdashti, TJ Herzog, JS Rader, MA Powell, RK Gibb, ... Gynecologic oncology 95 (3), 546-551, 2004 | 213 | 2004 |
| Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis R Vargas, JA Rauh-Hain, J Clemmer, RM Clark, A Goodman, ... Gynecologic oncology 133 (2), 216-220, 2014 | 198 | 2014 |
| Complications of pelvic radiation in patients treated for gynecologic malignancies AN Viswanathan, LJ Lee, JR Eswara, NS Horowitz, PA Konstantinopoulos, ... Cancer 120 (24), 3870-3883, 2014 | 182 | 2014 |
| Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial JF Liu, C Herold, KP Gray, RT Penson, N Horowitz, PA Konstantinopoulos, ... JAMA oncology 5 (12), 1731-1738, 2019 | 175 | 2019 |
| Placental site trophoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities NS Horowitz, DP Goldstein, RS Berkowitz Gynecologic oncology 144 (1), 208-214, 2017 | 162 | 2017 |
| Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer? DE Cohn, NS Horowitz, DG Mutch, SM Kim, T Manolitsas, JM Fowler Gynecologic oncology 87 (3), 243-246, 2002 | 155 | 2002 |
| Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma NS Horowitz, WA Peters III, MR Smith, CW Drescher, M Atwood, TP Mate Obstetrics & Gynecology 99 (2), 235-240, 2002 | 146 | 2002 |
| When ‘never-events’ occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial … LR Duska, L Garrett, M Henretta, JS Ferriss, L Lee, N Horowitz Gynecologic oncology 116 (3), 374-377, 2010 | 145 | 2010 |
| Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma JA Rauh-Hain, CC Nitschmann, MJ Worley Jr, LS Bradford, RS Berkowitz, ... Gynecologic oncology 129 (1), 63-68, 2013 | 142 | 2013 |
| Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva BE Howitt, HH Sun, MGM Roemer, A Kelley, B Chapuy, E Aviki, C Pak, ... JAMA oncology 2 (4), 518-522, 2016 | 127 | 2016 |
| Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer JA Rauh-Hain, N Rodriguez, WB Growdon, AK Goodman, DM Boruta, ... Annals of surgical oncology 19, 959-965, 2012 | 123 | 2012 |
| Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma BE Howitt, S Hanamornroongruang, DI Lin, JE Conner, S Schulte, ... The American journal of surgical pathology 39 (3), 287-293, 2015 | 112 | 2015 |
| Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational … SY Sun, A Melamed, DP Goldstein, MR Bernstein, NS Horowitz, AF Moron, ... Gynecologic oncology 138 (1), 46-49, 2015 | 107 | 2015 |
| Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma JF Liu, N Xiong, SM Campos, AA Wright, C Krasner, S Schumer, ... Journal of Clinical Oncology 39 (14), 1531-1539, 2021 | 105 | 2021 |
| Universal screening for mismatch-repair deficiency in endometrial cancers to identify patients with Lynch syndrome and Lynch-like syndrome JC Watkins, EJ Yang, MG Muto, CM Feltmate, RS Berkowitz, NS Horowitz, ... International Journal of Gynecological Pathology 36 (2), 115-127, 2017 | 98 | 2017 |
| Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer C Wan, MP Keany, H Dong, LF Al-Alem, UM Pandya, S Lazo, K Boehnke, ... Cancer research 81 (1), 158-173, 2021 | 97 | 2021 |
